Errata (DOI:10.1016/S1474-4422(06)70327-1);Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: A multicentre, double-blind, randomised, placebo-controlled study

Lancet Neurology

Volumn 5, Issue 3, 2006, Pages 213-220

  Filippi, Massimo ^a   Wolinsky, Jerry S ^b   Comi, Giancarlo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; PLACEBO;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ADULT; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INFLAMMATION; INFLUENZA; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; NAUSEA; NERVE DEGENERATION; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL DISORDER; PAIN; PARESTHESIA; PHARYNGITIS; POPULATION SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCREENING; SENSORY DYSFUNCTION; SIDE EFFECT; SINUSITIS; SKIN MANIFESTATION; SLEEP DISORDER; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE; VITAL SIGN;

EID: 32544449771     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70428-8     Document Type: Erratum

References (18)

1. MB Bornstein, A Miller, S Slagle A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis N Engl J Med 317 1987 408 414
2. KP Johnson, BR Brooks, JA Cohen Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial Neurology 45 1995 1268 1276
3. KP Johnson, BR Brooks, JA Cohen Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability Neurology 50 1998 701 708
4. G Comi, M Filippi, JS Wolinsky the European-Canadian Glatiramer Acetate Study Group The European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing-remitting multiple sclerosis Ann Neurol 49 2001 290 297
5. M Filippi, M Rovaris, MA Rocca Glatiramer acetate reduces the proportion of new MS lesions evolving to black holes Neurology 57 2001 731 733
6. F Martinelli Boneschi, M Rovaris, KP Johnson Glatiramer acetate and relapse rate in multiple sclerosis: meta-analysis of three double-blind, randomised, placebo-controlled clinical trials Mult Scler 9 2003 349 355
7. MP Sormani, P Bruzzi, G Comi, M Filippi The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis Mult Scler 11 2005 447 449
8. PW Duda, MC Schmied, SL Cook, JI Krieger, DA Hafler Glatiramere acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis J Clin Invest 105 2000 967 976
9. O Neuhaus, C Farina, A Yassouridis Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells Proc Natl Acad Sci USA 97 2000 7452 7457
10. C Farina, MS Weber, E Meinl, H Wekerle, R Hohlfeld Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action Lancet Neurol 4 2005 567 575
11. JS Wolinsky Glatiramer acetate for the treatment of multiple sclerosis Expert Opin Pharmacother 5 2004 875 891
12. CM Poser, DW Paty, L Scheinberg New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 1983 227 231
13. JF Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
14. KP Johnson, BR Brooks, JA Cohen Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial Neurology 57 suppl 5 2001 S16 S24
15. M Rovaris, M Filippi, G Calori Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images J Neurol 244 1997 266 270
16. M Rovaris, G Comi, MA Rocca, JS Wolinsky, M Filippi the European/Canadian Glatiramer Acetate Study Group Short term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications Brain 124 2001 1803 1812
17. DA Hafler, HL Weiner Immunologic mechanisms and therapy in multiple sclerosis Immunol Rev 144 1995 75 107
18. A Chaudhuri, PO Behan Multiple sclerosis is not an autoimmune disease Arch Neurol 61 2004 1610 1612